Table 3.
Clinical Outcomes With Genotype‐Guided Therapy or Conventional Therapy in Patients With High and Low ABCD‐GENE‐Score
| Variable |
High (≥10) ABCD‐GENE score (n=1014) |
Low (<10) ABCD‐GENE score (n=3700) |
Pint | ||||
|---|---|---|---|---|---|---|---|
| GGT | CT | HR (95% CI) | GGT | CT | HR (95% CI) | ||
| Time to first event analysis | |||||||
| All‐cause death, MI, or stroke | 3.7% | 5.2% | 0.70 (0.38–1.28) | 2.4% | 2.7% | 0.91 (0.60–1.37) | 0.49 |
| Cardiovascular death, MI, stroke, definite or probable ST, or severe recurrent ischemia | 5.8% | 8.1% | 0.70 (0.44–1.14) | 4.4% | 4.5% | 0.97 (0.71–1.33) | 0.27 |
| All‐cause death | 1.0% | 2.0% | 0.53 (0.19–1.52) | 1.0% | 1.0% | 1.06 (0.55–2.05) | 0.27 |
| Major/minor bleeding | 1.9% | 1.6% | 1.13 (0.44–2.91) | 1.1% | 1.0% | 1.10 (0.59–2.08) | 0.97 |
Estimates are calculated by the Kaplan‒Meier method.
ABCD‐GENE indicates Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping; CT, conventional therapy; GGT, genotype‐guided therapy; HR, hazard ratio; MI, myocardial infarction; and ST, stent thrombosis.